Indian Pharma

Health min urges stakeholders to build trust in quality of Indian drugs

Union Health Minister Mansukh Mandaviya urged all the stakeholders on Sunday to steadfastly work towards building trust and confidence in the quality of Indian drugs, cosmetics and medical devices in domestic and export markets. It is of critical importance to ensure that the country's regulatory mechanisms are of impeccable standards that are sustained over time and space, Mandaviya said as he inaugurated a two-day "chintan shivir" on "Drugs: Quality Regulations and Enforcement" in Hyderabad. "How can we ensure that the confidence of the consumers of pharmaceuticals manufactured in India is upheld? I urge all the stakeholders to steadfastly work towards making the Indian drugs regulatory system among the best in the world, which could be emulated by other countries," he said. In his inaugural address, Mandaviya underlined the focus of the deliberative forum, saying, "The chintan shivir is a platform for all the stakeholders in the pharma and health sectors to deliberate on pathways

Lupin Pharma launches Lurasidone Hydrochloride Tablets in US

The generic equivalent of Latuda tablets has been launched in the US markets

Indian pharma R&D spends stay stagnant three years after pandemic downturn

Spends are now lower relative to sales than before Covid-19, stand at 4.4% of net sales, compared with 20% in the US

Cough syrup-linked deaths: Manufacturing activities stopped at Noida firm

All manufacturing activities at Marion Biotech's Noida unit have been stopped in view of reports of contamination of its cough syrup, Dok-1 Max, Union Health Minister Mansukh Mandaviya said on Friday. Further investigation in connection with the death of 18 children in Uzbekistan allegedly linked to the cough syrup is going on, the minister said in a tweet. "Following inspection by @CDSCO_INDIA_INF team in view of reports of contamination in cough syrup Dok1 Max, all manufacturing activities of Marion Biotech at NOIDA unit have been stopped yesterday night, while further investigation is ongoing," Mandaviya said. Government sources said Uzbek officials reached out to India on Thursday night regarding the cough syrup-linked deaths and seeking a thorough probe in the matter. A legal representative of the company had said on Thursday that the manufacturing of Dok-1 Max has stopped "for now". Marion Biotech does not sell Dok-1 Max in India and its only export has been to Uzbekistan, a

After Gambia, now Uzbekistan alleges Indian cold drug killed its children

Noida-based Marion Biotech's Dok-1 Max anti-cold medicine under scanner after the Central Asian nation blames it for 18 deaths

Zuventus first in world to launch aviptadil for ARDS commercially

Discovered in 1970, the drug was tested on severe Covid-19 patients on DCGI's direction

Who is responsible for the quality of Indian pharma exports?

WHO has issued a global alert over four cough syrups made by an Indian pharma company, for alleged death of 66 children in The Gambia. Who are responsible for quality checks of Indian pharma exports?

TMS Ep276: OPEC production cuts, Indian pharma exports, stocks, USB-C ports

How will OPEC production cuts affect India? Who is responsible for the quality of Indian pharma exports? Are consumption stocks a good bet now? What makes USB-C the best charging port? Answers here

Who is responsible for the quality of Indian pharma exports?

WHO has issued a global alert over four cough syrups made by an Indian pharma company, for alleged death of 66 children in The Gambia. Who are responsible for quality checks of Indian pharma exports?

Udaan to provide medicine delivery to pharmacies every 4-hour

As part of the new service offering, Udaan will provide medicine delivery to pharmacies every 4-hour with 4 delivery slot options in a day to order medicines across six cities

Indian pharma industry likely to grow to $130 bn by 2030, says IPA

The trade shows are jointly organised by Indian Pharma Machinery Manufacturers Association (IPMMA), Indian Analytical Instruments Association (IAIA) and Messe Muenchen

Inter-ministerial MoU inked for promotion of 'One Herb, One Standard'

A memorandum of understanding (MoU) was inked between the Pharmacopoeia Commission for Indian Medicine and Homoeopathy (Ministry of Ayush) and the Indian Pharmacopoeia Commission (Ministry of Health) here on Tuesday for inter-ministerial cooperation for the promotion and facilitation of "One Herb, One Standard". P K Prajapati, Director (in-charge) of the Pharmacopoeia Commission for Indian Medicine and Homoeopathy (PCIM&H), and Rajeev Singh Raghuvanshi, Secretary-cum-Scientific Director of the Indian Pharmacopoeia Commission (IPC), signed the MoU in the presence of Rajesh Kotecha, Secretary, Ministry of Ayush, according to a statement issued by the ministry. On the occasion, Kotecha said, "The primary objective of this MoU is the development of cooperative efforts between the PCIM&H and the IPC to promote public health by facilitating the development of harmonised herbal drug standards. Since both the PCIM&H and the IPC are working with the common cause, it is logical and .

Indian pharma industry may rebound to 8-11% growth rate, says Alkem

Alkem Laboratories expects the Indian pharmaceutical industry to rebound to 8-11 per cent growth rate with normalcy in activities as the pandemic eases out

Pharma SMEs stock up on a month's raw material amid supply disruptions

The lockdown in various Chinese provinces, including Shanghai, is likely to delay shipments by two weeks to a month, said domestic players.

Expand PLI scheme for pharma to make it research-linked, says industry

So far 55 drug manufacturers have been selected under the PLI scheme for pharma.

Govt removes export curbs on Remdesivir, active pharmaceutical ingredients

The Centre has also removed similar curbs for exports of organic LEDs (Light Emitting Diodes) and liquid crystals

US pricing pressure cloud over Indian pharma growth, say analysts

Complex pipeline, execution, and regulatory compliance hold key

Aurobindo Pharma net profit dips 22% to Rs 604 cr in December quarter

The Hyderabad-based drug maker had reported a consolidated net profit of Rs 777.3 crore in the same period of previous fiscal

Glenmark gets nod from US Food & Drug Administration for generic drug

Glenmark Pharmaceuticals on Friday said its US-based unit has received approval from the US health regulator to market Metronidazole Vaginal gel, in the American market. The drug firm has received final approval by the United States Food & Drug Administration (USFDA) for its product which is a generic version of Bausch Health US LLC's MetroGel-Vaginal, the drug firm said in a statement. According to IQVIA sales data for the 12-month period ending November 2021, the MetroGel-Vaginal Gel achieved annual sales of approximately around USD 60.4 million. Glenmark's current portfolio consists of 173 products authorised for distribution in the US marketplace and 46 ANDA's pending approval with the USFDA. In addition to these internal filings, the drug firm continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, Glenmark noted.

Hyderabad's Biophore to manufacture ingredients of Pfizer's Covid drug

Biophore India Pharmaceutical announced that it developed and started manufacturing the key intermediates of Nirmatrelvir, one of the active ingredients of Paxlovid, the latest anti-Covid therapy